Results 1 to 10 of about 2,780 (142)

Cardiovascular Problems in the Fragile X Premutation [PDF]

open access: yesFrontiers in Genetics, 2020
There is a dearth of information about cardiovascular problems in fragile X premutation carriers who have 55–200 CGG repeats in fragile X mental retardation 1 (FMR1) gene.
Nattaporn Tassanakijpanich   +6 more
doaj   +7 more sources

Fragile X Premutation Associated Conditions (FXPAC) [PDF]

open access: yesFrontiers in Pediatrics, 2020
The European Fragile X Network (EFXN) proposes that Fragile X Premutation Associated Conditions (FXPAC) be adopted as a universal term covering any condition linked to the Fragile X premutation.
Kirsten Johnson   +2 more
doaj   +5 more sources

Fragile X Premutation: Medications, Therapy and Lifestyle Advice [PDF]

open access: yesPharmacogenomics and Personalized Medicine, 2021
Deepika Kour Sodhi,1 Randi Hagerman1,2 1The MIND Institute, University of California Davis Health, Sacramento, CA, USA; 2Department of Pediatrics, University of California Davis Health, Sacramento, CA, USACorrespondence: Randi HagermanUC Davis MIND ...
Sodhi DK, Hagerman R
doaj   +7 more sources

Prevalence and implications of fragile X premutation screening in Thailand [PDF]

open access: yesScientific Reports
The fragile X premutation is a public health concern worldwide. Implementing a comprehensive screening program for FMR1 premutation alleles could empower individuals and families with information, supporting informed health decisions and potentially ...
Areerat Hnoonual   +3 more
doaj   +4 more sources

Clinical and molecular correlates in fragile X premutation females [PDF]

open access: yeseNeurologicalSci, 2017
The prevalence of the fragile X premutation (55–200 CGG repeats) among the general population is relatively high, but there remains a lack of clear understanding of the links between molecular biomarkers and clinical outcomes.
Poonnada Jiraanont   +13 more
doaj   +6 more sources

Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on FMR1 Premutation [PDF]

open access: yesCells, 2023
The premutation of the fragile X messenger ribonucleoprotein 1 (FMR1) gene is characterized by an expansion of the CGG trinucleotide repeats (55 to 200 CGGs) in the 5’ untranslated region and increased levels of FMR1 mRNA. Molecular mechanisms leading to
Flora Tassone   +45 more
doaj   +2 more sources

Executive Function and Working Memory Deficits in Females with Fragile X Premutation [PDF]

open access: yesLife, 2023
The Fragile X premutation is a genetic instability of the FMR1 gene caused by 55–199 recurrences of the CGG sequence, whereas there are only 7–54 repeats of the CGG sequence in the normal condition.
Osnat Segal   +3 more
doaj   +2 more sources

Fragile X-Associated Neuropsychiatric Disorders (FXAND) in Young Fragile X Premutation Carriers. [PDF]

open access: yesGenes (Basel), 2022
Background: The fragile X premutation carrier state (PM) (55–200 CGG repeats in the fragile X messenger ribonucleoprotein 1, FMR1 gene) is associated with several conditions, including fragile X-associated primary ovarian insufficiency (FXPOI) and fragile X-associated tremor ataxia (FXTAS), with current literature largely primarily investigating older ...
Aishworiya R   +5 more
europepmc   +5 more sources

Aging in Fragile X Premutation Carriers. [PDF]

open access: yesCerebellum, 2016
It is now recognized that FMR1 premutation carriers (PC) are at risk to develop a range of neurological, psychiatric, and immune-mediated disorders during adulthood. There are conflicting findings regarding the incidence of hypertension, hypothyroidism, diabetes, and cancer in these patients that warrant further study.
Lozano R   +8 more
europepmc   +7 more sources

Fragile x premutation. [PDF]

open access: yesJ Neurodev Disord, 2014
Whereas full mutation CGG-repeat expansions (>200 repeats) of the fragile X gene (FMR1) give rise to the neurodevelopmental disorder, fragile X syndrome (FXS); smaller, 'premutation' expansions (55 to 200 repeats) are now gaining increasing recognition as the basis for a spectrum of clinical involvement, from neurodevelopmental problems; to mid-adult ...
Tassone F, Hagerman PJ, Hagerman RJ.
europepmc   +6 more sources

Home - About - Disclaimer - Privacy